Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (GB:0IFZ)
LSE:0IFZ
RESEARCH TOOLSreports
Carisma Therapeutics (0IFZ) Share Price & Analysis
0 Followers
0IFZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$65.80 - $65.80
Previous Close$65.8
Volume0.00
Average Volume (3M)N/A
Market Cap
$70.21M
Enterprise Value-$4.28M
Total Cash (Recent Filing)$77.61M
Total Debt (Recent Filing)$3.12M
Price to Earnings (P/E)N/A
Beta0.00
Next Earnings
May 09, 2024EPS EstimateN/A
Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,542,534
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.66
R-Squared0.87
Alpha0.36
Financial Highlights & Ratios
Price to Book (P/B)2.66
Price to Sales (P/S)1.45
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.05
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$8.75Price Target Upside-86.70% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Carisma Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCarisma Therapeutics Inc. is focused on developing innovative CAR-myeloid cell therapies, with the lead therapeutic CT-0508 showing promise in treating solid tumors.
Financial HealthCarisma extends financial runway into 3Q25 following workforce reduction and strategic pipeline focus, indicating a strengthened financial position.
Strategic PartnershipsThe partnership with Moderna for in-vivo macrophage therapies and the potential for $3B+ in milestones and royalties demonstrates strong industry validation of Carisma's innovative approach.
Bears Say
Corporate StrategyCARM is ceasing further development of its lead candidate, CT-0508, and prioritizing CT-0525, which has not yet entered the clinic.
Drug EfficacySteroid administration likely reversed the effects of CT-0508 in the initial patients.
Financial HealthCARM announced a reduction in workforce by 37%, which may signal cost-cutting measures due to financial constraints.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
0IFZ FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest share price was $65.80 and its highest was $65.80 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Currently, no data Available
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Carisma Therapeutics’s earnings last quarter?
Carisma Therapeutics released its earnings results on Apr 01, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.433 by -$0.087.
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.36 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Carisma Therapeutics have?
Currently, no data Available
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Carisma Therapeutics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.433. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Carisma Therapeutics?
Among the largest hedge funds holding Carisma Therapeutics’s share is Hussman Strategic Advisors Inc. It holds Carisma Therapeutics’s shares valued at N/A.
---
Carisma Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (-86.70% Downside)
$8.75 (-86.70% Downside)
Blogger Sentiment
Bullish
GB:0IFZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.85%
12-Months-Change
Fundamentals
Return on Equity
-94.06%
Trailing 12-Months
Asset Growth
-67.03%
Trailing 12-Months
Company Description
Carisma Therapeutics
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
---
0IFZ Stock 12 Months Forecast
Average Price Target
$8.75
▼(-86.70% Downside)
Technical Analysis
Carisma Therapeutics
―
Atreca
―
BioMarin Pharmaceutical
―
CareDx
―
Crinetics Pharmaceuticals
―
Best Analysts Covering 0IFZ
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-51.02%
reiterated a buy rating 8 days ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.02% per trade.
---